Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2020.0723
Abstract: Importance Risankizumab selectively inhibits interleukin 23, a cytokine that contributes to psoriatic inflammation. Objective To evaluate the efficacy and safety of risankizumab vs placebo and continuous treatment vs withdrawal in adults with moderate to severe… read more here.
Keywords: week; treatment withdrawal; treatment; patients receiving ... See more keywords
Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial
Sign Up to like & getrecommendations! Published in 2018 at "International Clinical Psychopharmacology"
DOI: 10.1097/yic.0000000000000200
Abstract: We assessed the efficacy of pexacerfont, a CRF1 antagonist, for the treatment of withdrawal symptoms. In this randomized, double-blind, placebo-controlled clinical trial, male patients with amphetamine or opioid dependence, on the basis of the Diagnostic… read more here.
Keywords: dependence; trial; treatment withdrawal; placebo ... See more keywords